A Phase 2 Proof of Concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of OMS906 in PNH Patients with a Sub-optimal Response to the C5 inhibitor, Ravulizumab

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-501190-39-01

Acronym

OMS906-PNH-001

Enrollment

Registered

2022-11-14

Start date

2023-05-15

Completion date

2024-10-10

Last updated

2024-06-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Paroxysmal nocturnal hemoglobinuria

None listed

Sex/Gender

All

Age

18 Years to No maximum

Germany, Greece

None listed

Source: EU CTIS · Data processed: Feb 4, 2026